Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



@@#116300@@

Joint Bone Spine
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le samedi 12 octobre 2019
Doi : 10.1016/j.jbspin.2019.08.001
accepted : 29 August 2019
Exposure to TNF antagonist therapies induces variations of the gut microbiota in an in vivo model using healthy mice
 

Odile Gabay a, , Jonathan Vicenty a, Autumn Zack-Taylor a, Linda Tiffany a, Grant Wunderlin a, Dylan Smith a, Lismari Reyes-Munoz a, Vivienne Edwards a, Wells W. Wu b, Je-Nie Phue b, Luis Santana-Quintero d, Phuc VinhNguyen Lam c, Kathleen A. Clouse a
a U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA 
b U.S. Food and Drug Administration, Center for Biologicals Evaluation and Research, Facility for Biotechnology Resources, Silver Spring, MD, USA 
c U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, HIVE, Silver Spring, MD, USA 
d U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Hematology and Oncology Products, Silver Spring, MD, USA 

Corresponding author at: FDA/CDER White Oak, Division of Biotechnology Review and Research, Bldg 52/72, Rm2321, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.FDA/CDER White Oak, Division of Biotechnology Review and Research, Bldg 52/72, Rm232110903 New Hampshire AvenueSilver SpringMD20993USA
Highlights

There is currently no study on the impact of biologic therapeutics on the microbiome, despite variable patients’ response to biologics used to treat gut-joint-axis diseases.
We studied microbiome variations resulting from different TNF-antagonist treatments in an in vivo mouse model.
We showed a dysbiosis of the microbiome after treatment in young mice, and identified major bacteria involved in TNF-antagonists exposure. These bacteria were different between males and females.

The full text of this article is available in PDF format.

Keywords : Gut microbiome, TNF inhibitors, Dysbiosis



 Disclaimer: This manuscript reflects the views of the authors and should not be construed to represent FDA's views or policies.



© 2019  Published by Elsevier Masson SAS.